Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Awareness, knowledge, and preferences of United States (US) patients with chronic lymphocytic leukemia (CLL) and their caregivers related to finite duration (FD) therapy and minimal (Measurable) residual disease (MRD)
    Meeting Abstract

    Koffman, B.; Stewart, C.; Avruch, L.; Bailey, N.; Brumble, R.; Byrd, J. C.; Danilov, A. V.; Davids, M. S.; Furman, R.; Jain, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Practice gaps and barriers in optimal care among healthcare providers treating patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): Results of a two-phase qualitative/quantitative study
    Meeting Abstract

    Becker, M. N.; Howson, A.; Quill, T. A.; Daver, N.; Stein, E. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Disease-modifying potential of bet inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis - preliminary Data
    Meeting Abstract

    Verstovsek, S.; Salama, M. E.; Mascarenhas, J.; Talpaz, M.; Mesa, R. A.; Vannucchi, A.; Rampal, R.; Oh, S. T.; Olteanu, H.; Chiu, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K.; Fenske, T. S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • ERK2 substrate binding domains perform opposing roles in pathogenesis of a JAK2V617F-driven myeloproliferative neoplasm
    Meeting Abstract

    Truong, B.; Zhang, Y.; Fahl, S.; Qcai, K.; Martinez, E.; Al-Saleem, E.; Gong, Y.; Liebermann, D.; Soboloff, J.; Dunbrack, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world management of patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens: Results from the AML Real World Evidence (ARC) Initiative
    Meeting Abstract

    Vachhani, P.; Wolach, O.; Garcia, J. S.; Zeidner, J. F.; Talati, C.; Pollyea, D. A.; Lai, C.; Moshe, Y.; Abedin, S.; Lavie, D.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Gilteritinib (GILT) monotherapy with addition of decitabine (DEC) in non-responders in older newly diagnosed (ND) FLT3 mutated acute myeloid leukemia (AML) patients having high and low variant allele frequency (VAF): A phase 2/1b sub-study of the Beat AML Master Trial
    Meeting Abstract

    Traer, E.; Huang, Y.; Mims, A. S.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; Schiller, G. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Outcomes of chronic lymphocytic leukemia and Richter Transformation following discontinuation of noncovalent Bruton's Tyrosine Kinase inhibitors
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Pagel, J. M.; Jensen, J. L.; Battiato, K. E.; Fox, Y.; Meyer, K.; Bailey, N.; Rhodes, J. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Addressing a new challenge in chronic lymphocytic leukemia: Outcomes of therapies after exposure to both a covalent Bruton's Tyrosine Kinase Inhibitor and venetoclax
    Meeting Abstract

    Thompson, M. C.; Roeker, L. E.; Coombs, C. C.; Jensen, J. L.; Kamdar, M.; Skarbnik, A.; Pagel, J. M.; Bailey, N.; Pu, J. J.; Jacobs, R.; more...
    Blood (2021)

    Fulltext@MSK | Save